The company abandons TNG908, but is still all in on the troubled target.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

It’s back to school for biotech, with a packed conference schedule.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.